

Alain M Schoepfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/642033/publications.pdf>

Version: 2024-02-01

114
papers

7,407
citations

147566

31
h-index

54797

84
g-index

115
all docs

115
docs citations

115
times ranked

4222
citing authors

#	ARTICLE	IF	CITATIONS
1	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 3-20.e6.	1.5	1,839
2	Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. <i>United European Gastroenterology Journal</i> , 2017, 5, 335-358.	1.6	718
3	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018, 155, 1022-1033.e10.	0.6	712
4	Delay in Diagnosis of Eosinophilic Esophagitis Increases Risk for Stricture Formation in a Time-Dependent Manner. <i>Gastroenterology</i> , 2013, 145, 1230-1236.e2.	0.6	580
5	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. <i>Gut</i> , 2016, 65, 524-531.	6.1	279
6	Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2016, 150, 581-590.e4.	0.6	251
7	Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 332-341.	0.9	240
8	Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 147, 1255-1266.e21.	0.6	221
9	Eosinophilic Esophagitis: Analysis of Food Impaction and Perforation in 251 Adolescent and Adult Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 598-600.	2.4	217
10	Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate. <i>American Journal of Gastroenterology</i> , 2013, 108, 1744-1753.	0.2	175
11	Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 74-86.e15.	0.6	170
12	Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept. <i>American Journal of Gastroenterology</i> , 2017, 112, 1527-1535.	0.2	105
13	Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 159, 1672-1685.e5.	0.6	88
14	Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. <i>Liver International</i> , 2017, 37, 707-716.	1.9	70
15	Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 419-428.e6.	2.4	66
16	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2474-2484.e3.	2.4	57
17	Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endoscopic severity or biomarkers. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 412-418.	0.6	54
18	Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 473-483.e17.	2.4	54

#	ARTICLE	IF	CITATIONS
19	Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update. <i>Digestion</i> , 2020, 101, 2-15.	1.2	53
20	Emerging treatment options for extraintestinal manifestations in IBD. <i>Gut</i> , 2021, 70, 796-802.	6.1	45
21	How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients?. <i>American Journal of Gastroenterology</i> , 2015, 110, 402-414.	0.2	44
22	Expression Patterns of TNF α , MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 347-354.	0.6	44
23	Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. <i>BMC Gastroenterology</i> , 2017, 17, 138.	0.8	42
24	Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1399-1409.	0.6	40
25	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	1.5	40
26	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 116-126.	0.2	39
27	Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1334-1342.	0.6	38
28	High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 191-199.	0.6	37
29	Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis. <i>MAbs</i> , 2017, 9, 927-944.	2.6	37
30	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1292-1301.	0.6	37
31	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	2.4	33
32	Eosinophilic Esophagitis: Relationship of Subepithelial Eosinophilic Inflammation With Epithelial Histology, Endoscopy, Blood Eosinophils, and Symptoms. <i>American Journal of Gastroenterology</i> , 2018, 113, 348-357.	0.2	32
33	Celiac disease diagnosis still significantly delayed—Doctor's but not patients' delay responsive for the increased total delay in women. <i>Digestive and Liver Disease</i> , 2016, 48, 1148-1154.	0.4	30
34	Creating a multi-center rare disease consortium—the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Translational Science of Rare Diseases</i> , 2017, 2, 141-155.	1.6	30
35	Update on basic and clinical aspects of eosinophilic oesophagitis. <i>Gut</i> , 2014, 63, 1355-1363.	6.1	29
36	Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 750-759.	1.9	29

#	ARTICLE	IF	CITATIONS
37	EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1256-1263.	0.5	29
38	Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1200-1205.	0.6	28
39	Management of the Elderly Inflammatory Bowel Disease Patient. <i>Digestion</i> , 2020, 101, 105-119.	1.2	27
40	Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). <i>International Journal of Epidemiology</i> , 2019, 48, 385-386f.	0.9	26
41	Comparison of different biopsy forceps models for tissue sampling in eosinophilic esophagitis. <i>Endoscopy</i> , 2016, 48, 1069-1075.	1.0	24
42	Adults with eosinophilic oesophagitis identify symptoms and quality of life as the most important outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1082-1090.	1.9	24
43	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. <i>United European Gastroenterology Journal</i> , 2020, 8, 1196-1207.	1.6	24
44	Treatment of Fibrostenotic and Fistulizing Crohn's Disease. <i>Digestion</i> , 2012, 86, 23-27.	1.2	23
45	Food-induced immediate response of the esophagus—A newly identified syndrome in patients with eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 339-347.	2.7	22
46	Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, and Eosinophilic Colitis: Common Mechanisms and Differences between East and West. <i>Inflammatory Intestinal Diseases</i> , 2016, 1, 63-69.	0.8	21
47	Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 766-775.e4.	2.4	21
48	Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 245-247.	0.9	20
49	Eosinophilic esophagitis: What can we learn from Crohn's disease?. <i>United European Gastroenterology Journal</i> , 2017, 5, 762-772.	1.6	20
50	Eosinophilic esophagitis: latest insights from diagnosis to therapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 84-93.	1.8	20
51	Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1842-1844.	2.4	19
52	Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 269-276.	0.6	19
53	Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2514-2523.e2.	2.4	19
54	Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 35-45.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1126-1137.e2.	0.5	18
56	Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis. <i>United European Gastroenterology Journal</i> , 2022, 10, 308-318.	1.6	17
57	Serial Fecal Calprotectin Measurements to Detect Endoscopic Recurrence in Postoperative Crohn's Disease: Is Colonoscopic Surveillance No Longer Needed?. <i>Gastroenterology</i> , 2015, 148, 889-892.	0.6	16
58	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1477-1488.e10.	2.4	16
59	Dilation Modifies Association Between Symptoms and Esophageal Eosinophilia in Adult Patients With Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 2098-2102.	0.2	16
60	Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2485-2494.e15.	2.4	16
61	Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1125-1132.	0.6	15
62	Current concepts in eosinophilic esophagitis. <i>Allergo Journal International</i> , 2017, 26, 258-266.	0.9	15
63	Emerging Therapies for Eosinophilic Gastrointestinal Diseases. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3276-3281.	2.0	15
64	Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multi-center study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2520-2533.	2.7	15
65	Management of non-functional pancreatic neuroendocrine tumors by endoscopic ultrasound-guided radiofrequency ablation: Retrospective study in two tertiary centers. <i>Digestive Endoscopy</i> , 2022, 34, 1207-1213.	1.3	14
66	Activity Assessment of Eosinophilic Esophagitis. <i>Digestive Diseases</i> , 2014, 32, 98-101.	0.8	13
67	Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland. <i>Advances in Therapy</i> , 2021, 38, 660-677.	1.3	13
68	Pharmacologic Treatment of Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 77-88.	0.6	12
69	Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. <i>Digestion</i> , 2020, 101, 683-691.	1.2	12
70	Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 912-919.e2.	0.5	12
71	Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 329-344.	1.0	11
72	Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 748-755.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6â€week openâ€label trial of the EOSâ€2 Programme. <i>United European Gastroenterology Journal</i> , 2022, 10, 330-343.	1.6	11
74	Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECs). <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 163-170.	0.8	10
75	Treatment of Eosinophilic Esophagitis by Dilation. <i>Digestive Diseases</i> , 2014, 32, 130-133.	0.8	9
76	Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 25-29.	1.1	9
77	Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies. <i>Digestive Diseases</i> , 2016, 34, 462-468.	0.8	8
78	Eosinophilic esophagitis: current perspectives from diagnosis to management. <i>Annals of the New York Academy of Sciences</i> , 2016, 1380, 204-217.	1.8	8
79	Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 1169-1193.	0.9	8
80	Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1729-1738.e1.	2.4	8
81	Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1159-1167.	0.8	7
82	Assessment of endoscopic Doppler to guide hemostasis in high risk peptic ulcer bleeding. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1311-1318.	0.6	7
83	Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 868-875.	0.8	7
84	Systematic Assessment of Adult Patientsâ€™ Satisfaction with Various Eosinophilic Esophagitis Therapies. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 211-220.	0.9	7
85	Increasing Incidence of Microscopic Colitis in a Population-Based Cohort Study in Switzerland. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2205-2206.	2.4	6
86	Total and activity-induced energy expenditure measured during a year in children with inflammatory bowel disease in clinical remission remain lower than in healthy controls. <i>Clinical Nutrition</i> , 2020, 39, 3147-3152.	2.3	6
87	Crohnâ€™s versus Cancer: Comparison of Functional and Surgical Outcomes after Right-Sided Resections. <i>Digestive Diseases</i> , 2021, 39, 106-112.	0.8	6
88	Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohnâ€™s disease patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1875771.	1.4	5
89	Symptom-based patient-reported outcomes in adults with eosinophilic esophagitis: value for treatment monitoring and randomized controlled trial design. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 169-174.	1.1	5
90	Varicella Zoster Virus in Inflammatory Bowel Disease Patients: What Every Gastroenterologist Should Know. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 316-325.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 825-834.	0.6	4
92	The "Red Flag Instrument"™ for Early Detection of Crohn's Disease: Is it ready for Clinical Practice?: Figure 1.. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 597-598.	0.6	4
93	Editorial: Serial Fecal Calprotectin and Lactoferrin Measurements for Early Diagnosis of Pouchitis After Proctocolectomy for Ulcerative Colitis: Is Pouchoscopy No Longer Needed?. <i>American Journal of Gastroenterology</i> , 2015, 110, 888-890.	0.2	4
94	Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2654-2663.	1.1	4
95	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 773-780.	1.6	4
96	Patient-Reported Outcomes in Eosinophilic Esophagitis and Achalasia. Current Treatment Options in <i>Gastroenterology</i> , 2016, 14, 51-60.	0.3	3
97	The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. <i>Digestive and Liver Disease</i> , 2017, 49, 268-272.	0.4	3
98	Follow-Up Ileocolonoscopy Is Underused in Crohn's Disease Patients after Ileocecal Resection despite Higher Total and Inpatient Health-Care Costs Compared to Controls. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 100-108.	0.8	3
99	Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2456-2462.	2.4	2
100	Positioning of dilation in eosinophilic oesophagitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 192-194.	8.2	1
101	Adult EOE Patients' Satisfaction with Different EOE-Specific Treatment Modalities. <i>Gastroenterology</i> , 2017, 152, S863-S864.	0.6	1
102	Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 144-153.	0.8	1
103	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2385-2386.	2.4	1
104	Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 350-357.	0.8	1
105	Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.2	1
106	Body composition assessment in children with inflammatory bowel disease: A comparison of different methods. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 1414-1419.	0.4	1
107	Gastrointestinal quality of life before and short- and long-term after Roux-en-Y gastric bypass for severe obesity. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1583-1590.	1.0	1
108	Reply. <i>Gastroenterology</i> , 2014, 146, 1426-1427.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Editorial: fluticasone propionate orally disintegrating tablets“interesting concept but is it going anywhere? Authors“™ reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 990-991.	1.9	0
110	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. Gastroenterology, 2021, 161, 778-784.	0.6	0
111	A Response to: Letter to the Editor Regarding “Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland“™. Advances in Therapy, 2021, , 1.	1.3	0
112	Benefit of radiofrequency ablation after widespread endoscopic resection of neoplastic Barrett“™s esophagus in daily practice. Annals of Gastroenterology, 2021, 35, 34-41.	0.4	0
113	“sophagite ““osinophiles“: update 2022. Paediatrica, 2022, 33, .	0.0	0
114	“sophagite ““osinophiles“: update 2022. Paediatrica, 2022, 33, .	0.0	0